Our new Japanese recruitment team delivers volunteer panels - already!

Posted:
16
December 2004

Volunteers enjoying a study

Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.As a result of the continued growth in the demand for Bridging Studies, Richmond Pharmacology have developed a dedicated in-house approach to the recruitment of Japanese volunteer panels.Wendy Galloway, Head of Volunteer Recruitment, commented: “We recognised the need to introduce a stronger means of recruiting Japanese volunteers. Consequently, in September we recruited 5 bilingual Japanese recruitment managers and have introduced a specialist marketing strategy to support this. I am delighted with the results – in just 2 months since the launch we have successfully delivered 2 Japanese volunteer panels. Our campaigns currently stretch across the UK and Germany and through this approach we are already ahead of target for the New Year's requirements. This means we continue to offer our clients a volunteer recruitment guarantee on every Phase I study.”Richmond Pharmacology is Europe's largest provider of Japanese/Caucasian Bridging Studies and has a dedicated Japanese recruitment brand and department. For more information click here.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more